Monotherapy or One-Two Punch Against EGFR-Mutant NSCLC?

Standard of care for patients with EGRF+ lung cancer is treatment with an EGRF targeted drug, but should this be monotherapy, or should it be combined with chemotherapy and/or other drugs?
Medscape Medical News

source https://www.medscape.com/viewarticle/967443?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?